SCHEMBL17875792

SCHEMBL17875792

c1ccc2c(c1)oc1ccc(-c3ccc4c(c3)-c3cc(-c5ccc6oc7ccccc7c6c5)ccc3CSC4)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
NPC1 O15118 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 1/20 0.44
AHR P35869 2/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
PLA2G2A P14555 4/20 0.38
PLA2G4A P47712 4/20 0.38
CASP3 P42574 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17875788 0.96 MEN1 (0.41) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875733 0.94 MAPT (0.40) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875795 0.93 PLA2G2A (0.43) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875785 0.91 AHR (0.44) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875740 0.91 MEN1 (0.37) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875786 0.91 ALOX5 (0.39) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875811 0.90 ALOX5 (0.52) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875744 0.89 PLA2G2A (0.40) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875766 0.89 PLA2G2A (0.40) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL17875798 0.88 KMT2A (0.38) MAPTSMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-03 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CRY2, CCNE2 MAPT 2144/4885SMN1; SMN2 3237/4885KDM4E 3120/4885
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 MAPT 2144/4885SMN1; SMN2 3237/4885KDM4E 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.